Overview Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the first FDA conditionally approved medication specifically developed to manage feline hypertrophic cardiomyopathy (HCM). Formulated for oral use in cats, Felycin®-CA1 contains sirolimus, which helps regulate pathways involved in abnormal heart muscle thickening.

  • Offers a new approach to feline cardiac care, improving treatment consistency and compliance
  • Delayed-release tablets formulated for cats
  • Oral administration supports at-home use
  • Designed to improve quality of life in cats with hypertrophic cardiomyopathy